Phenotyping patients with ischaemic heart disease at risk of developing heart failure: an analysis of the HOMAGE trial.

Date publication

novembre 2023

Journal

ESC heart failure

Auteurs

Membres identifiés du Cancéropôle Est :
Pr ROSSIGNOL Patrick

Tous les auteurs :
Santos-Ferreira D, Diaz SO, Ferreira JP, Girerd N, Pellicori P, Mariottoni B, Cosmi F, Hazebroek M, Verdonschot JAJ, Cuthbert J, Petutschnigg J, Heymans S, Staessen JA, Pieske B, Edelmann F, Clark AL, Rossignol P, Fontes-Carvalho R, Cleland JGF, Zannad F

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/37939716

Résumé

We aim to characterize the clinical and proteomic profiles of patients at risk of developing heart failure (HF), with and without coronary artery disease (CAD) or prior myocardial infarction (MI).

Mots clés

Coronary artery disease, Heart failure, Myocardial infarction, Proteomics, Spironolactone

Référence

ESC Heart Fail. 2023 11 8;: